Clinicopathological characteristics and prognosis of uterine sarcoma: a 10-year retrospective single-center study in China

Wang, Jin-feng; Li, Chen; Yang, Jing-yi; Wang, Yue-ling; Ji, Jing

doi:10.1186/s13000-024-01517-x

Table 2 Univariate analysis for PFS and OS using the log-rank tests in total cohort and subgroups

From: Clinicopathological characteristics and prognosis of uterine sarcoma: a 10-year retrospective single-center study in China

	Total cohort						ESS						LMS
	PFS			OS			PFS			OS			PFS			OS
	5-year rate (%)	mean	P	5-year rate (%)	mean	P	5-year rate (%)	mean	P	5-year rate (%)	mean	P	5-year rate (%)	mean	P	5-year rate (%)	mean	P
All	66.5	89.41		71.0	94.03		80.4	99.56		84.9	103.69		52.2	76.05		58.3	83.46
Age at diagnosis
≤ 50	80.6	105.7	0.004	82.7	110.3	0.005	90.5	115.0	0.022	88.8	114.6	0.108
>50	46.9	62.6		55.1	73.8		66.0	77.5		80.0	92.9
≤ 51													72.2	94.8	0.022	77.8	103.3	0.006
>51													15.0	37.5		24.4	47.7
Menopausal state
premenopausal	78.5	102.4	0.001	82.1	106.2	0.001	91.3	111.3	0.022	90.6	114.8	0.057	68.2	93.0	0.001	76.7	100.0	<0.001
postmenopausal	41.1	50.3		45.0	55.3		60.6	48.5		74.0	55.1		0	23.0		0	31.0
CDFI
No	81.6	89.2	0.289	85.6	93.9	0.191	71.6	80.5	0.341	77.9	87.7	0.405	90.0	92.1	0.046	90.0	93.1	0.098
yes	57.9	85.1		65.7	90.4		88.2	111.6		94.1	109.8		29.2	54.6		42.2	69.2
unknown	66.6	76.3		65.8	83.4		75.0	87.4		72.9	96.7		53.3	62.1		53.3	66.6
Tumor size (cm)
<5	92.9	94.7	0.093	92.9	95.3	0.2	100.0	/	0.277	100.0	/	0.406	100.0	/	0.31	100.0	/	0.499
≥ 5	54.1	80.7		61.7	86.6		71.4	/		79.5	/		40.3	/		49.1	/
miss	84.6	92.6		84.6	101.1		83.3	/		83.3	/		85.7	/		85.7	/
FIGO Stage
I	74.7	98.6	0.001	80.0	103.8	<0.001	83.6	103.1	0.177	85.4	109.4	0.252	67.8	94.4	<0.001	77.4	101.0	<0.001
II-IV	27.3	38.2		34.1	49.0		60.0	69.0		80.0	75.8		0	12.6		0	28.3
miss	0	24.0		0	31.0								0	24.0		0	31.0
Pathological type
ESS	80.4	99.6	0.131	84.9	103.7	0.202	/	/		/	/		/	/		/	/
LMS	52.2	76.1		58.3	83.5		/	/		/	/		/	/		/	/
Adenosarcoma	66.7	66		66.7	69.2		/	/		/	/		/	/		/	/
Histologic grade
low	79.6	99.1	0.137	86.2	104.7	0.097	90.2	110.5	0.003	94.1	118.3	0.001	60.6	74.4	0.059	71.6	80.1	0.026
high	52.2	59.8		53.1	62.7		75.0	52.0		82.5	56.4		0	27.7		0	37.5
miss	58.8	83.9		64.7	92.3		33.3	21.2		33.3	26.2		66.7	95.2		75.0	105.2
Myometrial invasion
<1/2	92.2	116.3	0.001	96.4	122.3	0.001	100.0	120.3	0.016	100.0	124.0	0.064	88.9	114.8	0.069	100.0	127.0	0.012
≥ 1/2	44.8	55.1		52.8	62.2		57.1	59.0		70.1	67.1		35.3	48.1		41.2	55.8
unknown	74.1	82.7		69.4	80.9		85.7	92.7		85.7	93.1		53.3	32.3		40.0	34.4
LVSI
no	67.3	90.6	0.071	72.2	95.4	<0.001	81.0	/	0.005	85.9	/	<0.001	54.1	79.0	0.178	60.8	87.0	0.103
yes	66.7	73.5		66.7	75.2		100.0	/		/	/		33.3	28.2		33.3	31.5
miss	0	11		0	14		0	/		0	/
Treatment plan
surgery	50.7	/	0.615	48.2	/	0.305	81.8	59.7	0.999	81.8	60.5	0.554	25	39.8	0.32	25.0	47.2	0.212
surgery + adjuvant therapy	68.9	/		75.7	/		80.0	99.6		86.9	105.7		58.4	81.4		66.1	88.9
Lymphadenectomy
no	62.6	85.6	0.478	69.7	91.4	0.636	79.8	91.9	0.899	87.2	93.3	0.992	43.9	66.4	0.203	53.6	78.3	0.435
yes	75.0	91.8		74.1	97.3		81.8	99.1		80.8	105.2		70.0	81.5		68.6	81.7
Chemotherapy regimen
IAP	51.4	56.9	0.241	64.0	64.2	0.224	71.4	/	0.74	80.0	/	0.909	42.9	45.7	0.464	57.1	53.5	0.218
PT	77.0	100.0		82.1	105.9		81.3	/		87.5	/		68.2	91.6		72.7	100.5
other	75.0	31.1		75.0	32.6		100.0	/		/	/		50.0	16.8		50.0	19.8

Note: & age categorization was based on the mean age of each group. PFS: Progression-free survival; OS: Overall survival; CA125: carbohydrate antigen 125; CDFI: color Doppler flow imaging; FIGO: International Federation of Gynecology and Obstetrics; LMS: leiomyosarcoma; ESS: endometrial stromal sarcoma; LVSI: lymphovascular space invasion; IAP: Ifosfamide + epirubicin + Cisplatin; PT: Paclitaxel + platinum

Back to article page

ISSN: 1746-1596

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diagnostic Pathology

Contact us